Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Multiple Myeloma

Treatment of Multiple Myeloma The management of multiple myeloma (MM) has undergone many developments in the last 30 years. Initially, melphalan was used as a single agent and this was followed by the discovery of corticosteroids as highly active agents and the design of multiagent cytotoxic regimens. However, although response rates have improved, little impact has been achieved on survival. Interferon has been extensively examined in early as well as relapsed disease. Currently, a benefit in survival is only evident in maintenance phase, where there is a small but significant difference. However, this has to be evaluated in the context of adverse effects and the impact on quality of life. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Treatment of Multiple Myeloma

Loading next page...
 
/lp/springer-journals/treatment-of-multiple-myeloma-clKLHTbaPe
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403010-00005
Publisher site
See Article on Publisher Site

Abstract

The management of multiple myeloma (MM) has undergone many developments in the last 30 years. Initially, melphalan was used as a single agent and this was followed by the discovery of corticosteroids as highly active agents and the design of multiagent cytotoxic regimens. However, although response rates have improved, little impact has been achieved on survival. Interferon has been extensively examined in early as well as relapsed disease. Currently, a benefit in survival is only evident in maintenance phase, where there is a small but significant difference. However, this has to be evaluated in the context of adverse effects and the impact on quality of life.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References